Clinical trials
Lupus Erythematosus clinical trials
Below are recruiting lupus erythematosus clinical trials, each written for real people, not researchers. We’re tracking 261 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07107659RecruitingEarly Phase 1
Testing ONT01 for active lupus
This trial tests a new drug called ONT01 for people with active lupus that is not affecting their kidneys. It is for those who have not had success with standard treatments.
New York, New YorkAges 18 years+ - NCT07109986RecruitingPhase 1
Study of UB-VV410 for active lupus or lupus nephritis
This trial tests a new treatment, UB-VV410, for people with active systemic lupus erythematosus (SLE) or lupus nephritis (kidney inflammation caused by lupus) that hasn't responded to standard treatments. It aims to see if this therapy can help control the disease.
NanjingAges 18–65 - NCT07394361Enrolling by invitation
Clinical Pilates for women with lupus: fatigue and quality of life
This study tests whether clinical Pilates training can help reduce fatigue, improve mood, sleep, and overall quality of life in women with systemic lupus erythematosus. If you have low disease activity and are not already exercising regularly, you may be able to participate.
Adana, SaricamAges 18–55 - NCT05352919Enrolling by invitationPhase 3
Long-term study of litifilimab for lupus symptom control
This study follows people with systemic lupus erythematosus (SLE) who already took part in an earlier, 1-year placebo-controlled trial. It looks at the long-term safety of litifilimab and whether it helps improve lupus symptoms over time.
Phoenix, ArizonaAges 18 years+ - NCT07323173RecruitingPhase 1
Safety study of LBL-047 in healthy adults and lupus patients
This study tests a new drug called LBL-047 in healthy people and in people with mild to moderate lupus. It helps check if the drug is safe and how the body processes it. Participating may help find better treatments for lupus.
Bengbu, AnhuiAges 18–60 - NCT06617325RecruitingPhase 3
New drug for moderate to severe lupus
This study tests a new medicine called Dapirolizumab Pegol (given as an infusion) for people with moderate to severe lupus (SLE) that is not well controlled despite standard treatments. It aims to see if the drug can reduce lupus activity and prevent flares.
Avondale, ArizonaAges 16 years+ - NCT04976322Enrolling by invitationPhase 3
Long-term lupus treatment safety study with dapirolizumab
This Phase 3 study tests whether dapirolizumab pegol is safe and tolerable for people with systemic lupus erythematosus (SLE) when taken long-term. You may be offered a chance to stay on this medicine if the study team thinks you could benefit.
Birmingham, AlabamaAges 16 years+ - NCT07515014RecruitingPhase 2
Testing E6742 in Systemic Lupus Erythematosus
This study tests a new medicine called E6742 to help people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. Researchers want to see if this drug can reduce lupus symptoms and disease activity.
Bengbu, AnhuiAges 18–75 - NCT07430306RecruitingPhase 3
Study of anifrolumab for lupus patients not yet on strong treatments
This trial tests if a new drug called anifrolumab can help treat lupus in people who haven't taken strong medications like biologics or immunosuppressants before. It looks at overall disease activity and the chance to reduce steroid use.
Anniston, AlabamaAges 18–70 - NCT07447986RecruitingPhase 2
Testing a New Injection for Lupus (SLE)
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
Beijing, Beijing MunicipalityAges 18–70 - NCT07332481RecruitingPhase 3
Testing enpatoran for lupus affecting the skin
This trial tests if a drug called enpatoran can help people with lupus that causes skin rashes, like discoid lupus or subacute cutaneous lupus. It may be for those with or without systemic lupus.
Los Angeles, CaliforniaAges 18–75 - NCT07694336RecruitingPhase 2
Quinacrine for skin lupus
This study tests if quinacrine, an oral drug, improves skin rashes caused by lupus. You may be eligible if you have a type of skin lupus called SCLE or DLE that hasn't improved with standard treatments like steroids or hydroxychloroquine.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07720310Enrolling by invitation
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new immune cell therapy (CAR-T) for people with lupus that hasn't gotten better with standard treatments. The goal is to see if these modified cells can calm the overactive immune system and improve symptoms.
Lyasny, Minsk OblastAges 18–70 - NCT05688696RecruitingPhase 2
Testing a drug called orelabrutinib for lupus symptoms in adults
This Phase 2 trial studies whether orelabrutinib can improve systemic lupus erythematosus (SLE) and check its safety. It may help people with active lupus who are already on stable lupus medicines.
Bengbu, AnhuiAges 18–75 - NCT05988216Recruiting
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new type of immune cell therapy (CAR-T cells) for people with lupus that has not responded well to standard treatments. It aims to reset the immune system to reduce lupus activity.
Hangzhou, ZhejiangAges 18–65 - NCT06010472RecruitingEarly Phase 1
Car-NK cell therapy for lupus
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
ShanghaiAges 18–65 - NCT06032923RecruitingPhase 1/Phase 2
Does vitamin B3 boost help lupus symptoms?
This study tests whether a form of vitamin B3, called nicotinamide riboside, can improve immune function and reduce inflammation in women with mild to moderate lupus. It may help understand if boosting NAD+ levels offers a new way to manage the disease.
Bethesda, MarylandAges 18–120 - NCT06106906RecruitingPhase 1/Phase 2
CD19 CAR-T for Active Lupus
This study tests a new treatment called CD19 CAR-T, which reprograms your own immune cells to attack lupus. It is for people with active lupus that has not responded well to standard therapies.
Wuhan, HubeiAges 18–70 - NCT06106893RecruitingPhase 1/Phase 2
Study of CD19 CAR-γδT cells for active lupus
This trial is testing a new type of immune cell therapy (called CD19 universal CAR-γδT cells) for people with active lupus that hasn't been well controlled by standard treatments. The goal is to see if these specially designed cells can calm the immune system and reduce lupus symptoms.
Wuhan, HubeiAges 18–70 - NCT06232304Recruiting
Program for young people with childhood lupus
This study tests a program to help teenagers and young adults with childhood-onset lupus manage symptoms like fatigue, sadness, or pain. It aims to improve daily life and well-being.
Birmingham, AlabamaAges 12–22 - NCT06261021RecruitingPhase 2
Ruxolitinib cream for discoid lupus study
This trial tests a cream (ruxolitinib) on discoid lupus skin lesions. It aims to see if the cream can reduce DLE symptoms in adults.
Fredericton, New BrunswickAges 18 years+ - NCT06857214RecruitingPhase 1
GNC-038 antibody study for moderate to severe lupus
This trial tests a new antibody treatment, GNC-038, for people with moderate to severe lupus. It aims to see if it's safe and effective. You must have stable lupus treatment and active B cells in your blood.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06340750RecruitingPhase 1
BAFF CAR-T cells for lupus that hasn't improved with standard treatments
This trial tests a new type of cell therapy called BAFF CAR-T cells (LMY-920) for lupus that hasn't gotten better with standard treatments. It aims to see if these special immune cells can help calm the overactive immune system in lupus.
Columbus, OhioAges 18–65 - NCT06349343RecruitingPhase 1
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
WuhanAges 18–70
Hear when a new Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus erythematosus?
- Yes. Clin2 currently lists 261 recruiting lupus erythematosus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus erythematosus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus erythematosus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.